Nav: Home

Gut microbiome may predict response to biologic therapy for inflammatory bowel disease

May 15, 2017

Analysis of a patient's gut microbiome - the microbial population of the gastrointestinal tract - may be able to predict the likelihood of successful treatment for inflammatory bowel disease (IBD) with biologic drugs that target immune system activity. In their report published in Cell Host and Microbe, researchers from Massachusetts General Hospital (MGH) and the Broad Institute of MIT and Harvard describe differences in both the composition and the function of the gut microbiome between patients for whom treatment with a monclonal antibody-based drug was and was not effective in inducing remission of IBD symptoms.

"We are currently limited in our ability to predict which patients will respond to which therapies," says Ashwin Ananthakrishnan, MBBS, of the MGH Division of Gastroenterology, lead author of the paper. "Our finding that the pre-treatment composition and function of intestinal bacteria could predict treatment response offers an novel additional tool for personalized therapy choice."

Inflammatory bowel diseases like Crohn's disease and ulcerative colitis are autoimmune disorders in which the immune system turns on the body's own tissues, in this case the gastrointestinal tract. Traditional therapies include anti-inflammatory and immunosuppressive drugs, but the biologic drugs introduced in recent years more precisely target specific aspects of the immune response and have had superior results in many but not all patients with IBD or other autoimmune conditions.

Previous efforts to determine which patients might respond to particular biologic drugs based on their symptoms and on gene expression in the affected tissues have had only modest success. Since considerable recent research has found that the gut microbiome has an important role in several immune system disorders, the research team investigated whether it might also determine response to biologic treatment for IBD.

The study enrolled 85 patients - 43 with ulcerative colitis and 42 with Crohn's disease - who initiated treatment with vedolizumab (Entyvio), a monoclonal-antibody-based biologic that prevents white blood cells from migrating to inflammatory intestinal tissue. Stool samples taken before vedolizumab treatment and 14, 30 and 54 weeks into treatment were analyzed both for the composition of the microbial population and for functional qualities, based on expression patterns of microbial genes.

Participants who met criteria for remission of IBD symptoms at 14 weeks were found to have a more diverse pretreatment microbial population - with a greater abundance of potentially anti-inflammatory species - than did participants not achieving remission. Even more striking were differences in microbial functional patterns between those who did and did not achieve remission - both before treatment and 14 weeks into treatment. For those who were in remission at 14 weeks, microbial changes observed at that point persisted for at least a year, indicated that early changes could identify patients likely to achieve and maintain response to treatment.

While Ananthakrishnan, an assistant professor of Medicine at Harvard Medical School (HMS), notes that the current costs of microbiome sequencing make its use for routine screening impractical, technological improvements are like to reduce those costs. "The ability to pick the treatment most likely to work for a patient would be enormously helpful both in helping achieve remission quickly and in avoiding exposures to drugs that would be unlikely to work, may be costly and may have adverse side effects," he says. "In addition to testing this approach in larger groups of patients and with different drugs to see if it can reveal comparative effectiveness, we hope to use this data to develop targeted probiotics that may be able to adjust the population in those with an unfavorable baseline microbiome."
-end-
Ramnik Xavier, MD, PhD - chief of the MGH Division of Gastroenterology, an institute member at the Broad, and the Isselbacher Professor of Medicine in Gastroenterology at HMS - is senior author of the Cell Host and Microbe paper. Chengwei Luo, PhD, of the Broad Institute is co-lead author. Additional co-authors are Vijay Yajnik, MD, Hamed Khalili, MD, John Garber, MD, and Thomas Cleland, MGH Gastroenterology; and Betsy Stevens, Harvard Medical School. Support for the study includes National Institutes of Health grants DK097142, DK43351, DK92405 and P30 DK043351; and grants from the Crohn's and Colitis Foundation and the Helmsley Charitable Trust.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, genomic medicine, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Inflammatory Bowel Disease Articles:

Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.
FODMAPs diet relieves symptoms of inflammatory bowel disease
New research from King's College London has found that a diet low in fermented carbohydrates has improved certain gut symptoms and improved health-related quality of life for sufferers of inflammatory bowel disease (IBD).
The diet-microbiome connection in inflammatory bowel disease
A change in diet is a go-to strategy for treating inflammatory bowel diseases like Crohn's.
Edinburgh is global hotspot for inflammatory bowel disease rates
Edinburgh has some of the highest known rates of inflammatory bowel disease in the world and the figure is expected to rise in the next 10 years.
Medication linked to increased risk of inflammatory bowel disease
Medications that target tumor necrosis factor alpha (TNFα), a protein involved in inflammation, have revolutionized the management of certain autoimmune diseases, but paradoxically, these agents might provoke the development of other autoimmune conditions.
Study provides insights into depression in people with inflammatory bowel disease
Depression is common in people with inflammatory bowel disease (IBD), but the actual causes of depression in this group are unknown.
Sunshine may decrease risk of inflammatory bowel disease
Children who spend half an hour a day outside in the sun reduce their risk of inflammatory bowel disease (IBD), according to new research from The Australian National University (ANU).
New prognostic test could enable personalised treatment of inflammatory bowel disease
Scientists at the University of Cambridge have developed a new test that can reliably predict the future course of inflammatory bowel disease in individuals, transforming treatments for patients and paving the way for a personalised approach.
Role of interventional inflammatory bowel disease in the era of biologic therapy
According to a new statement from a panel of national and international experts in gastroenterology, inflammatory bowel disease (IBD) and other areas, interventional (or therapeutic) IBD endoscopy has an expanding role in the treatment of disease and of adverse events from surgery.
Improving diagnosis leads to better outcomes in patients with inflammatory bowel disease
It is estimated that 3 million Americans live with inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
More Inflammatory Bowel Disease News and Inflammatory Bowel Disease Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.